EYPT (EyePoint) Accounts Payable: $18.81 Mil (As of Mar. 2026)


EYPT EyePoint Inc EYPT
34 GF Score
Price $14.00
GF Value $0.78
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Accounts Payable?

EyePoint EYPT -0.07% 34 Accounts Payable is $18.81 Mil as of Mar. 2026. GuruFocus rates EYPT with a GF Score™ of 34/100 and a GF Value™ of $0.78 (Significantly Overvalued). The stock has 7 warning signs investors should review.

EyePoint's Accounts Payable for the quarter that ended in Mar. 2026 was $18.81 Mil.

EyePoint's quarterly Accounts Payable increased from Sep. 2025 ($10.08 Mil) to Dec. 2025 ($10.49 Mil) and increased from Dec. 2025 ($10.49 Mil) to Mar. 2026 ($18.81 Mil).

EyePoint's annual Accounts Payable increased from Dec. 2023 ($6.50 Mil) to Dec. 2024 ($11.72 Mil) but then declined from Dec. 2024 ($11.72 Mil) to Dec. 2025 ($10.49 Mil).

EyePoint Accounts Payable Historical Data

* Premium members only.

The historical data trend for EyePoint's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Accounts Payable Chart

EyePoint Annual Data
Trend Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.39 5.92 6.50 11.72 10.49

EyePoint Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.42 19.69 10.08 10.49 18.81
EYPT
34GF Score
EyePoint Inc EYPT
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EyePoint Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $18.81 Mil mean?
EyePoint (EYPT) has a Accounts Payable of $18.81 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on EyePoint and its competitors.
Is EyePoint's Accounts Payable too high?
EyePoint's current Accounts Payable is $18.81 Mil. Overall, EyePoint has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Accounts Payable compare to SPTX and CRVS?
EyePoint's Accounts Payable of $18.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on EyePoint and its competitors. EyePoint's current Accounts Payable is $18.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (EYPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.78, compared to a current price of $14.00 — trading 1694.9% above its estimated fair value. The current Accounts Payable is $18.81 Mil. EyePoint's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For EyePoint (EYPT), the current Accounts Payable is $18.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $14.00 is trading 1694.9% above its estimated GF Value™ of $0.78. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Accounts Payable: $18.81 Mil
  • GF Value™: $0.78 vs. price of $14.00 (1694.9% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.00
Price
$0.78
GF Value